Adverse Events With Androgen Deprivation Therapy in Patients With Metastatic Prostate Cancer

Share this content:
Intermittent androgen deprivation therapy did not reduce long-term health-related events in patients with prostate cancer.
Intermittent androgen deprivation therapy did not reduce long-term health-related events in patients with prostate cancer.

Intermittent androgen deprivation therapy (ADT) did not reduce long-term health-related events in patients with metastatic prostate cancer when compared with continuous ADT, according to a study published online in JAMA Oncology.1

In this study, investigators sought to compare the long-term events such as cardiovascular and endocrine events between patients who had received intermittent or continuous ADT. Patients were determined to have had an adverse health event based on whether they had any hospital claim or at least 2 physician or outpatient claims 30 days apart for: ischemic and thrombotic events, endocrine events, sexual dysfunction, dementia, and depression.

A total of 1134 patients with metastatic prostate cancer were randomly assigned to receive continuous or intermittent ADT. Median age was 71.3 years and the most common long-term events were hypercholesterolemia (31%) and osteoporosis (19%)

Results showed that 10-year cumulative incidence of ischemic and thrombotic events was higher for those in the intermittent arm: 33% vs 24% for those in the continuous arm (HR, 0.69; = .02).

The authors concluded that older men who received intermittent ADT had no reduction in bone, endocrine, or cognitive events and an increased incidence of ischemic and thrombotic events.

Reference

  1. Hershman DL, Unger JM, Wright JD, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer [published online ahead of print December 23, 2015]. JAMA Oncol. doi: 10.1001/jamaoncol.2015.4655.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs